Hepatocellular Carcinoma — Written Clinical Reasoning

SAQ 1 — HCC in a cirrhotic patient: staging and management (15 marks, 30 minutes)

Prompt: Outline your assessment, the staging and diagnostic reasoning, the integrated management plan addressing each problem, and the communication framework. Justify each decision with reference to evidence. [1]

Model Answer

Step 1 — The diagnostic synthesis (3 marks): [1]

This man has a definite hepatocellular carcinoma (HCC) by non-invasive imaging criteria. The multiphase MRI shows the classic triad of arterial phase hyperenhancement, portal venous washout, and an enhancing capsule in a lesion over 2 cm in a cirrhotic liver — this is LI-RADS 5, which is diagnostic of HCC without the need for biopsy [2]. The rising AFP (from 12 to 180 ng/mL) corroborates the diagnosis, though the imaging alone suffices. A biopsy is NOT needed and carries a risk of tumour seeding (1 to 3 percent).

The diagnosis was made through the intended surveillance pathway — six-monthly ultrasound plus AFP detected the lesion early. The Singal 2014 meta-analysis confirmed that surveillance improves early-stage detection, curative treatment rates, and overall survival [3].

Step 2 — The staging (4 marks): [1]

I would stage this patient using the Barcelona Clinic Liver Cancer (BCLC) system, which integrates tumour burden, liver function, and performance status [2][1]:

• Tumour burden: single 4.2 cm lesion, no vascular invasion, no extrahepatic spread. This is early-stage tumour burden.
• Liver function: Child-Pugh A (score 5: bilirubin 18, albumin 36, INR 1.1, no ascites, no encephalopathy). Preserved liver function.
• Performance status: ECOG 0. Fully active. [1]

This places him at BCLC stage A (early) — the curative treatment stage. [1]

However, I must assess his portal pressure to determine the optimal curative modality. His platelet count of 95 x 10^9/L and the presence of small oesophageal varices suggest clinically significant portal hypertension (CSPH), which is a critical determinant: a patient with CSPH is at high risk of post-hepatectomy liver failure and decompensation, and resection becomes less favourable. I would confirm the portal pressure with a hepatic venous pressure gradient (HVPG) if available — a value above 10 mmHg confirms CSPH and shifts the decision toward transplant or ablation rather than resection [2].

Step 3 — The problem list (2 marks): [1]

1. BCLC A hepatocellular carcinoma — the central problem; needs curative therapy.
2. Cirrhosis with clinically significant portal hypertension — complicates resection; needs the portal pressure assessed.
3. Chronic hepatitis C (post-SVR) — the underlying cause; cirrhosis persists despite viral eradication.
4. Type 2 diabetes and hypertension — metabolic comorbidities that complicate surgery and systemic therapy.
5. Small oesophageal varices — need surveillance and possible primary prophylaxis.
6. Psychosocial impact — a new cancer diagnosis on top of chronic liver disease. [1]

Step 4 — The integrated management plan (5 marks): [1]

Pillar 1 — Curative treatment for the HCC: Because he has a single lesion under 5 cm, Child-Pugh A liver function, and BCLC A staging, he is eligible for curative therapy. The choice between resection, ablation, and transplant depends on the portal pressure and the transplant assessment: [1]

• If the HVPG is under 10 mmHg (no CSPH): surgical resection is the first-line option, with a five-year survival of 50 to 70 percent [2].
• If the HVPG is above 10 mmHg (CSPH confirmed): resection is high-risk, and the preferred options are liver transplant (within Milan criteria — he is within them: single lesion under 5 cm, no vascular invasion, no extrahepatic spread) or thermal ablation if the lesion is accessible and transplant is not feasible. Five-year post-transplant survival is around 70 percent with a recurrence rate under 15 percent [2][1].

I would refer him urgently to a multidisciplinary team (MDT) including hepatobiliary surgery, interventional radiology, transplant surgery, and hepatology to determine the optimal curative approach. I would list him for transplant assessment. [1]

Pillar 2 — Management of the underlying liver disease: The cirrhosis is the substrate for the HCC and for future tumours. His HCV is cured (SVR achieved), but the cirrhosis persists. I would ensure he remains under hepatology surveillance. His type 2 diabetes and hypertension need optimisation — metabolic syndrome drives NAFLD/NASH and may contribute to ongoing liver injury. I would screen for and manage his portal hypertension: non-selective beta-blocker (e.g., carvedilol 6.25 mg daily) for primary prophylaxis of variceal bleeding given his small varices and platelet count under 150 [2].

Pillar 3 — Ongoing surveillance: After curative treatment, surveillance continues with six-monthly ultrasound plus AFP for life — the cirrhotic liver can produce new tumours regardless of the treatment of the index lesion. If he receives a transplant, the surveillance shifts to monitoring for recurrence (chest CT, liver imaging, AFP) and for graft complications. [1]

Pillar 4 — Comorbidity management: Optimise his diabetes (HbA1c, glycaemic control) and blood pressure. Assess cardiovascular risk before any surgical intervention. Ensure his nutrition is adequate (sarcopenia is common in cirrhosis and worsens surgical outcomes). [1]

Step 5 — Communication (1 mark): [1]

I would explain the diagnosis in plain language: he has a liver cancer that was caught early by the surveillance programme, which is exactly what surveillance is designed to do. The treatment options — resection, ablation, or transplant — all offer a chance of cure. I would explain why the portal pressure assessment matters (it determines whether surgery is safe), and I would be honest about the lifelong commitment to surveillance. I would involve his GP, the transplant coordinator, the dietitian, and the hepatology nurse specialist, and I would document the shared decisions. [1]

SAQ 2 — Advanced HCC: the systemic therapy decision (10 marks, 20 minutes)

Prompt: A 70-year-old man with alcohol-related and NAFLD cirrhosis (Child-Pugh A) presents with HCC involving the main portal vein with tumour thrombus and a lung metastasis. His ECOG performance status is 1. He has had no variceal bleeding and has not had a recent endoscopy. Discuss the staging, the treatment options, the pre-treatment workup required, and the evidence base for the recommended therapy. [1]

Model Answer

Step 1 — The staging (2 marks): [1]

This man has BCLC stage C (advanced) HCC. The defining features are vascular invasion (main portal vein tumour thrombus) and extrahepatic spread (lung metastasis), with ECOG 1 (cancer-related symptoms). BCLC C is the systemic therapy stage — locoregional therapies (TACE, ablation) are no longer appropriate. The portal vein thrombus also contraindicates TACE (which requires a patent portal vein) [2][1].

Step 2 — The first-line systemic therapy and its evidence (4 marks): [1]

The recommended first-line therapy for BCLC C HCC in a Child-Pugh A patient is atezolizumab plus bevacizumab. The IMbrave150 trial (Finn 2020, NEJM) was a landmark phase 3 trial that randomised 501 patients with unresectable HCC to atezolizumab (a PD-L1 inhibitor) plus bevacizumab (a VEGF inhibitor) versus sorafenib. The combination significantly improved overall survival (median OS 19.2 months versus 13.4 months with sorafenib, HR 0.66) and progression-free survival [4]. This established the combination as the new first-line standard of care.

If he cannot receive or declines immunotherapy, the alternative first-line options are the single-agent tyrosine kinase inhibitors: sorafenib (the SHARP trial, Llovet 2008, showed median OS 10.7 months versus 7.9 months with placebo [5]) or lenvatinib (the REFLECT trial showed non-inferiority to sorafenib with median OS 13.6 months).

Step 3 — The mandatory pre-treatment workup (3 marks): [1]

Before starting atezolizumab plus bevacizumab, he MUST have an upper gastrointestinal endoscopy to screen for and treat oesophageal and gastric varices. Bevacizumab, by inhibiting VEGF, impairs mucosal healing and can precipitate catastrophic bleeding from untreated varices. If high-risk varices are found, they must be treated (endoscopic band ligation and/or non-selective beta-blocker) before starting bevacizumab. This is a non-negotiable safety step emphasised in the IMbrave150 protocol and subsequent guidelines [4].

Additional pre-treatment assessments: confirm Child-Pugh A liver function (the combination is approved for Child-Pugh A; evidence in Child-Pugh B is limited); screen for autoimmune disease (contraindication to checkpoint inhibitor); assess bleeding risk and cardiovascular risk (bevacizumab causes hypertension and arterial thromboembolism); baseline thyroid function and cortisol (checkpoint inhibitors cause endocrinopathies); and baseline imaging for response assessment. [1]

Step 4 — Second-line consideration (1 mark): [1]

If he progresses on or cannot tolerate first-line therapy, second-line options include regorafenib (RESORCE trial, median OS 10.6 months after sorafenib progression), cabozantinib, or ramucirumab (particularly if AFP above 400 ng/mL). [1]

I would communicate honestly about the prognosis: median overall survival with the best current systemic therapy is approximately 19 months, which is a substantial improvement on the historical 8 months with best supportive care, but is not curative. I would discuss goals of care, advance care planning, and the involvement of palliative care alongside active treatment. [1]